Articles related to KIDNEY CANCER/RCC

In a phase 3 trial comparing belzutifan to everolimus for advanced renal-cell carcinoma, belzutifan demonstrated a significant improvement in progression-free survival at 18 months (24.0% vs. 8.3%, P=0.002) and objective response rate (21.9% vs. 3.5%, P<0.001).

In the recent KEYNOTE-564 trial, adjuvant pembrolizumab therapy was shown to increase the 48-month overall survival rate to 91.2% compared to 86.0% with placebo among post-surgical patients with renal-cell carcinoma at increased risk of recurrence.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.

In the KEYNOTE-564 trial, adjuvant pembrolizumab demonstrated a significant improvement in disease-free survival among patients with renal-cell carcinoma at high risk of recurrence after nephrectomy, offering a new direction in post-surgical treatment strategies.

In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.